New drug for combination treatment of lung cancer approved in the USA

The United States has approved a new drug for the treatment of one of the types of lung cancer. The development of the pharmaceutical company Johnson & Johnson's will be used in combination with other chemotherapeutic agents.

According to Reuters, the US Food and Drug Administration (FDA) has approved a combination therapy called Rybrevant for patients with non-small cell lung cancer and a mutation in the EGFR protein that causes rapid tumor growth.

According to studies, Rybrevant in combination with chemotherapy reduces the risk of disease progression or death by 61% compared to chemotherapy alone.

In 2021, the FDA approved treatment with this drug under an accelerated regimen. Now, the effectiveness of Rybrevant has been confirmed by a phase III trial.

The FDA has also approved the drug for the treatment of locally advanced or metastatic non-small cell cancer for patients whose disease has progressed during or after chemotherapy.

"We are redefining the treatment of patients with non-small cell lung cancer, advancing innovative regimens that can be used in the early stages to extend people's lives," said Kiran Patel, a Johnson & Johnson specialist.

Non-small cell lung cancer (NSCLC) is the most common type of epithelial lung cancer with a high mortality rate. Its most common types are squamous cell, large cell, and adenocarcinoma.

Although NSCLC is associated with smoking, adenocarcinomas are also found in patients who have never smoked tobacco.

As OBOZ.UA previously reported, a revolutionary cancer treatment method has been launched in the UK. The Hammersmith Hospital in London has begun to apply mRNA therapy to cancer patients, which is based on the use of genetic material that transmits common tumor markers to the patient's immune system.

Only verified information is available on the OBOZ.UA Telegram channel and Viber. Do not fall for fakes!